💊 Pfizer’s RSV vaccine success; US FDA tackles drug shortages; Mapping the Marburg mayhem

#313 | Merck’s Austrian affair; India attempts reputation repair; Fake news? Indians don’t care

Hello, and welcome back to The Kable for Day 4 of what has been a really full week in the life sciences.

Lately, misinformation has been a growth industry around the world. India is no exception. What is exceptional, however, is this new survey that says 60% of Indians are susceptible to health misinformation online.

Merck/MSD has signed a new deal worth $2.5 billion with Austria's Proxygen on molecular glue degraders. The research collaboration and license agreement will see both companies jointly develop molecular glue degraders for as-yet-unspecified targets.

In excellent news on the RSV front, Pfizer has released final trial data for its RSV vaccine, saying it is 82% effective against severe infection in infants.

Equatorial Guinea's Marburg disease outbreak continues to grow with 5 new suspected cases of Marburg disease. A total of 1,159 contacts have been traced. More on the implications of this outbreak in Newsworthy today.

And finally, the AfDB is hosting a seminar next week on business opportunities in Africa. At The Kable, we believe this is an excellent seminar for all manners of life sciences companies to attend because there is no bigger opportunity than health in Africa.